The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. InMed Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. InMed Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.18 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
InMed Pharmaceuticals Receivables Turnover Related Terms
InMed Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for InMed Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INM vs SNOA, CVSI, PRFX: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMed Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals (INM) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on InMed Pharmaceuticals and its competitors. According to the industry distribution chart, InMed Pharmaceuticals ranks #43 out of 947 companies in the Drug Manufacturers industry, placing it in the top 4.5%.
Is InMed Pharmaceuticals' Receivables Turnover too high?
InMed Pharmaceuticals' current Receivables Turnover is 0.00. Based on the distribution chart, InMed Pharmaceuticals ranks #43 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Receivables Turnover compare to SNOA and CVSI?
According to the Drug Manufacturers industry distribution chart, InMed Pharmaceuticals ranks #43 out of 947 companies for Receivables Turnover. This places InMed Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on InMed Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMed Pharmaceuticals's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.93, compared to a current price of $1.65 — trading 77.4% above its estimated fair value. The current Receivables Turnover is 0.00. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMed Pharmaceuticals (INM) Overvalued in 2026?
Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued.
The current stock price of $1.65 is trading 77.4% above its estimated GF Value™ of $0.93.
GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INM:
Receivables Turnover: 0.00
GF Value™: $0.93 vs. price of $1.65 (77.4% above fair value)
No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score
Get the complete analysis for INM
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INM has been successfully added to your 
